Methylphenidate

# Research Output: Methylphenidate

## Chemical Identity

**Verified via PubChem CID 4158 [Ref 1]:**

| Property | Value | Source |
|---|---|---|
| PubChem CID | 4158 | PubChem [Ref 1] |
| Molecular formula | C₁₄H₁₉NO₂ | PubChem [Ref 1] |
| Molecular weight | 233.31 g/mol | PubChem [Ref 1] |
| IUPAC name | methyl 2-phenyl-2-piperidin-2-ylacetate | PubChem [Ref 1] |
| InChIKey | DUGOZIWVEXMGBE-UHFFFAOYSA-N | PubChem [Ref 1] |
| CAS number | 113-45-1 (racemate HCl salt: 298-59-9) | Koehm et al. 2010 [Ref 38] |

**Discrepancy notes:**
- The brief's SMILES, molecular formula, molecular weight, InChIKey, and PubChem CID fields are blank. These are now confirmed above from PubChem.
- The brief's systematic name "methyl 2-phenyl-2-piperidin-2-ylacetate" is confirmed correct per PubChem CID 4158.
- The characterization field is listed as "emerging" — **this is incorrect.** Methylphenidate has been in continuous clinical use since 1955, has an enormous published literature, and is the most prescribed ADHD medication globally. This should be reclassified as "well-established."

**Stereochemistry:**
Methylphenidate is marketed as the racemate dl-threo form. The pharmacologically active enantiomer is **d-threo-methylphenidate (dexmethylphenidate)**. After oral dosing, approximately 99% of circulating MPH is the d-enantiomer, because l-MPH undergoes extensive and rapid first-pass hydrolysis by carboxylesterase 1 (CES1) to inactive l-ritalinic acid (Patrick & Rodriguez 2019 [Ref 7]). The d-enantiomer is also approved separately as dexmethylphenidate (Focalin®). The erythro isomers of both enantiomers are pharmacologically inactive (Gatley et al. 1996 [Ref 3]).

**Physical properties:**
Published peer-reviewed data on melting point and aqueous solubility specific to MPH were not located via API searches. This is noted as a gap.

---

## Pharmacology

### Mechanism of Action

Methylphenidate is a **pure monoamine reuptake inhibitor**. It binds to and blocks the dopamine transporter (DAT) and norepinephrine transporter (NET), preventing synaptic reuptake and increasing extracellular concentrations of dopamine and norepinephrine. Unlike amphetamine, it does not trigger active monoamine release from vesicles (Spiller et al. 2013 [Ref 40]).

### Binding Affinity Data

From Gatley et al. (1996 [Ref 3]), using rat brain monoamine transporters and in vitro radioligand displacement assays:
- **Affinity order: DAT > NET >> SERT (5-HTT)**
- MPH and its derivatives showed no significant affinity for dopamine D1 (IC₅₀ > 500 nM) or D2 receptors (IC₅₀ > 5,000 nM)

**Important nuance on DAT vs NET affinity:** The Hannestad et al. (2010 [Ref 20]) PET study notes that "in vitro, the affinity of methylphenidate for the norepinephrine transporter (NET) is **higher** than that for the dopamine transporter (DAT)," and demonstrates that clinically relevant MPH doses significantly occupy brain NET in vivo. Published Ki values (from web-retrieved sources citing in vitro studies) cite approximately DAT Ki ~193 nM and NET Ki ~38 nM for d-threo-MPH — meaning NET has numerically higher affinity (lower Ki). The apparent discrepancy with "DAT > NET" in Gatley 1996 arises from reporting conventions (1/Ki vs. Ki) and differences between rat brain and human cloned transporter assays. **Flag for editorial review:** binding affinity values should be confirmed against a primary source using human cloned transporters.

### In Vivo Dopamine Mechanism (Human)

Volkow et al. (2001 [Ref 2]) used PET with [¹¹C]raclopride in 11 healthy controls and demonstrated that **oral methylphenidate at therapeutic doses (~0.8 mg/kg) produced a significant 20 ± 12% reduction in striatal D2 receptor availability** (p < 0.0005), indicating ~20% elevation of extracellular dopamine. This confirmed that therapeutic oral doses block DAT and meaningfully increase synaptic dopamine in humans.

Volkow et al. (2009 [Ref 16]) showed via PET that individuals with ADHD have reduced dopamine synaptic markers in the reward pathway, providing a neurobiological rationale for MPH's therapeutic mechanism.

Arnsten (2011 [Ref 30]) describes the PFC-level mechanism: norepinephrine strengthens PFC network connectivity via α₂A-adrenoceptors; dopamine sculpts inputs via D1 receptors to decrease noise. MPH indirectly amplifies these effects by blocking NET and DAT, increasing catecholamine tone in PFC circuits.

### Pharmacokinetics

Data synthesized from multiple sources:

**Oral route (immediate release):**
- **Bioavailability:** Approximately 20–30% (extensive first-pass hepatic/intestinal metabolism by CES1). d-MPH bioavailability is approximately 22–30%; l-MPH is only ~5% due to near-complete first-pass metabolism (Patrick & Rodriguez 2019 [Ref 7])
- **Tmax:** Approximately 1–2 hours for IR formulation
- **Half-life:** Approximately 2–3 hours (Markowitz & Melchert 2022 [Ref 5])
- **Protein binding:** Approximately 10–33% (low)
- **Linear PK:** Dose-proportional, though substantial interindividual variability exists (Markowitz & Melchert 2022 [Ref 5])

**Extended-release (OROS-Concerta, Quillivant, etc.):**
- Biphasic release profiles: typically 22% immediate-release pulse then extended release
- Various formulations achieve different Tmax/Cmax profiles; reviewed comprehensively in Patrick et al. (2019 [Ref 6])

**Metabolism:**
- **Primary pathway:** CES1 hydrolysis → inactive **ritalinic acid** (>90% of dose) — this is the main detoxification route (Markowitz & Melchert 2022 [Ref 5]; Zhang et al. 2025 [Ref 17])
- **Minor oxidative metabolites:** p-hydroxy-methylphenidate and 6-oxo-methylphenidate lactam (active, minor) — both formed via CYP enzymes
- CES1 genetic polymorphisms significantly affect plasma concentrations. The G143E variant (rs71647871) substantially impairs CES1 activity, increasing MPH and metabolite exposure (Stage et al. 2019 [Ref 19]; Zhang et al. 2025 [Ref 17])
- **CYP involvement:** Minimal; MPH is not a significant CYP substrate or inhibitor. This explains the rarity of CYP-based drug–drug interactions (Markowitz & Melchert 2022 [Ref 5])

**Ethanol interaction with metabolism:**
CES1 also metabolizes ethanol. Co-administration of ethanol competitively inhibits CES1, causing:
1. ~40% increase in d-MPH Cmax and ~25% increase in AUC (Patrick et al. 2007 [Ref 8])
2. Formation of the transesterification metabolite **ethylphenidate** (l-ethylphenidate primarily) via CES1 catalysis (Koehm et al. 2010 [Ref 38]; Patrick et al. 2014 [Ref 9])
3. Potentiation of euphoric effects and abuse liability (Zhu et al. 2017 [Ref 10])

Dexmethylphenidate (d-MPH only) largely bypasses the ethanol–l-MPH interaction but still potentiates d-MPH euphoria at maximum Cmax (Patrick et al. 2019 [Ref 6]).

**Intranasal (insufflated) route:**
Formal controlled PK studies of insufflated MPH are sparse in the peer-reviewed literature identified. Insufflation bypasses first-pass CES1 metabolism, increasing absolute bioavailability and rate of rise (analogous to IV vs. oral), which increases abuse liability and subjective euphoria (consistent with the rate hypothesis). Detailed published human PK data for insufflated IR-MPH were not found in this search; this is flagged as a gap.

---

## History

Methylphenidate was **first synthesized in 1944** by Swiss chemist **Leandro Panizzon** while working at Ciba Geigy (now Novartis) in Basel, Switzerland (Dodd et al. 2025 [Ref 21]; Wikipedia [Ref 22]). Panizzon named the compound after his wife, Marguerite "Rita" Panizzon, who used it to treat low blood pressure. Rita was, reportedly, the first person to use the compound recreationally and to describe stimulant effects to her husband.

Stimulant properties of methylphenidate were first formally recognized in the scientific literature around **1954**. In **1950**, Panizzon and Hartmann developed an improved synthesis and filed a US patent.

The FDA approved methylphenidate for medical use in the **United States in 1955**, initially for a broad array of conditions including depression, narcolepsy, and chronic fatigue (Dodd et al. 2025 [Ref 21]). In **1962**, the FDA approved Ritalin for use in children with behavioral problems — predating the formal recognition of Attention Deficit Hyperactivity Disorder (ADHD) as a diagnostic entity.

Methylphenidate became widely used in the US from the 1960s onward. It was placed under **Schedule II control** by the DEA under the Controlled Substances Act of **1970**, reflecting its abuse potential. International control followed under the **UN Convention on Psychotropic Substances (1971)**, where it was listed as Schedule II.

The landmark **MTA Cooperative Group trial (1999 [Ref 31])** — a 14-month RCT of treatment strategies for childhood ADHD — unequivocally demonstrated the superior efficacy of medication management (primarily MPH-based) over behavioral therapy alone for core ADHD symptoms. This cemented MPH as the first-line pharmacological treatment for ADHD.

In 2001, the FDA approved **dexmethylphenidate** (Focalin®), a "chiral switch" product using only the active d-enantiomer, at half the racemic dose. Extended-release formulations (Concerta, Metadate CD, Quillivant XR, Daytrana patch) were developed and approved through the 2000s to provide once-daily dosing.

---

## Subjective Effects

### From Controlled Studies in Healthy Adults

Dolder, Müller, Schmid, Borgwardt & Liechti (2018 [Ref 24]) conducted a double-blind, placebo-controlled, crossover study in healthy subjects directly comparing MDMA, methylphenidate, and modafinil at equally cardiostimulant doses. Key findings for methylphenidate:
- Produced **stimulant, alerting, and mildly euphoric effects**
- More sympathomimetic profile than MDMA at equivalent cardiostimulant doses
- Less prosocial and empathogenic character compared to MDMA
- Pronounced cardiovascular activation (heart rate, blood pressure increases)

Schmidt et al. (2017 [Ref 50]) demonstrated MPH's effects on response inhibition neural networks in healthy subjects.

Schmid et al. (2015 [Ref 25]) found that **methylphenidate (40 mg oral) significantly increased sexual arousal** for erotic stimuli in a placebo-controlled RCT of 30 healthy adults, confirming the dopaminergic basis of enhanced sexual drive (vs. MDMA which did not alter sexual arousal at serotonergic doses).

Kapur (2020 [Ref 27]) reviewed the literature on MPH as a cognitive enhancer in healthy adults and found **variable cognitive effects**, with benefit being **dose-, task-, and domain-dependent**. Improvements are most consistent in attention and vigilance tasks; working memory and executive function effects are less reliable. Non-specific subjective "productivity" effects may drive much non-medical use regardless of objective cognitive improvement.

Looby & Earleywine (2011 [Ref 21 cross-reference — not separately cited]) found that expectancy effects explain many subjective benefits reported by non-prescription users.

### Effect Domains Documented in Literature

The following effects from the brief's taxonomy are supported by published literature:

**Documented with good evidence:**
- **Stimulation** (sympathomimetic; universally documented)
- **Wakefulness** (indicated for narcolepsy; documented in RCTs)
- **Focus enhancement, thought organization, analysis enhancement** (therapeutic effect in ADHD; variable in healthy adults per Kapur 2020 [Ref 27])
- **Motivation enhancement** (dopaminergic mechanism; documented)
- **Appetite suppression** (established clinical side effect in ADHD trials)
- **Dry mouth** (established clinical side effect)
- **Increased heart rate, vasoconstriction** (sympathomimetic effects)
- **Sexual arousal enhancement** (documented in Schmid 2015 [Ref 25])
- **Anxiety** (dose-dependent; established adverse effect)
- **Insomnia/wakefulness** (established)
- **Pupil dilation** (mydriasis; documented in overdose literature [Ref 40])
- **Music enhancement** (user-reported; not formally studied in controlled contexts — label as user-report-only)
- **Compulsive redosing urge** (consistent with DAT blockade and dopaminergic reward dynamics; user-reported; limited formal study)
- **Bruxism** (reported in case series; consistent with catecholaminergic stimulation)
- **Excessive sweating, dehydration sensation** (sympathomimetic; documented)

**Documented with limited/case-level evidence:**
- **Cognitive euphoria** (documented in PET studies of striatal DA increase [Ref 2]; subjective quality varies)
- **Irritability, emotional suppression, depression** (documented rebound/adverse effects in ADHD patients; dose-dependent)
- **Ego inflation** (user-reported; no controlled study found)
- **Derealization** (rare; user-reported at high doses; consistent with dopaminergic excess)
- **Time alteration** (modest; user-reported; CYP literature on time perception and dopamine)

---

## Safety & Toxicity

### Acute Toxicity

**LD50 data (from Novartis Ritalin Safety Data Sheet — web-retrieved, not peer-reviewed [Ref 42 cross-ref]):**
- Oral LD50 in rats: approximately **367 mg/kg**
- IV LD50 in rats: approximately **50 mg/kg**
- Classification: Moderately toxic by oral route (Category III/IV standard classification)

**⚠️ FLAG:** LD50 values are sourced from SDS documentation, not peer-reviewed pharmacotoxicology studies. These values should be verified against published animal toxicology literature.

**Out-of-hospital toxicity threshold (human):** Emergency department referral recommended for:
- Ingestion of **> 2 mg/kg or 60 mg** (whichever is less) of immediate-release formulation (Scharman et al. 2007 [Ref 39])
- Ingestion of **> 4 mg/kg or 120 mg** of intact modified-release formulation
- Any ingestion in a patient chronically taking a MAOI

### Clinical Overdose Presentation

Spiller et al. (2013 [Ref 40]) describe the classic MPH/stimulant toxidrome:
- Neurological: agitation, tremor, hyperreflexia, hallucinations, delirium, paranoia, seizures, movement disorders
- Cardiovascular: hypertension, tachycardia, dysrhythmias
- Other: mydriasis, diaphoresis, hyperthermia, nausea

Primary mechanism of toxicity: **excessive extracellular dopamine, norepinephrine, and serotonin** (Spiller et al. 2013 [Ref 40]).

**Emergency management:** Largely supportive. First-line: benzodiazepines for agitation, dystonia, convulsions. Second-line for refractory cases: ziprasidone, haloperidol, dexmedetomidine, or propofol. ACLS for cardiac arrest/arrhythmia. **Fatalities are rare with appropriate care** (Spiller et al. 2013 [Ref 40]).

Over 8,000 MPH ingestions were reported to US poison centers in 2004 alone; by 2010, ~17,000 annual ADHD medication exposures were recorded (Spiller 2013 [Ref 40]).

### Cardiovascular Safety

- FAERS pharmacovigilance (2004–2021): MPH showed significant reporting odds ratios for **arrhythmias (ROR = 2.8, 95% CI 2.6–3.0)** and **palpitations (ROR = 3.1, 95% CI 2.9–3.3)** (Kandukuru et al. 2024 [Ref 13])
- Children on stimulants: statistically significant elevations in diastolic BP (69.7 vs. 65.8 mmHg, p=0.02) and heart rate (85.5 vs. 79.9 bpm, p=0.004) vs. placebo (Samuels et al. 2006 [Ref 15])
- Long-term MPH use in ADHD: echocardiographic study evaluated risk of hypertension, myocardial infarction, ventricular arrhythmia, cardiomyopathy (Tunca et al. 2025 [Ref 14])
- Risk magnitude appears low in healthy individuals but monitoring is warranted in those with underlying cardiovascular conditions (Vitiello 2008 [Ref 33])

### Psychiatric Adverse Effects

**Psychosis risk:**
- Large cohort study (n=20,586 pediatric MPH users): No increased risk of incident psychotic events during MPH exposure vs. non-exposed periods (IRR = 1.02, 95% CI 0.53–1.97). Elevated risk found **pre-exposure** (IRR = 4.64), suggesting underlying vulnerability rather than MPH causation (Man et al. 2016 [Ref 35])
- Individual case reports of MPH-induced hallucinations and brief psychosis exist (Martínez-Aguayo et al. 2017 [Ref 36])
- WHO VigiBase disproportionality analysis of MPH-associated psychotic symptoms in pediatric population is ongoing (Chrétien et al. 2026 [Ref 46])

**Growth suppression:**
- Temporary retardation of weight and height gain during prepubertal treatment; does not appear to affect adult stature if drug holidays are used (Roche et al. 1979 [Ref — unverifiable historical]; Vitiello 2008 [Ref 33]; Spencer et al. 2006 [Ref — see PubMed 16670649])

---

## Harm Reduction

### Key Risk Reduction Strategies (from published literature)

1. **Avoid MAOIs.** Any MPH dose in a patient on a MAOI requires immediate ED evaluation due to risk of hypertensive crisis (Scharman et al. 2007 [Ref 39]). This is an absolute contraindication.

2. **Avoid concurrent alcohol use.** Ethanol-CES1 interaction increases d-MPH Cmax by ~40%, forms ethylphenidate, potentiates euphoria and abuse liability (Patrick et al. 2007 [Ref 8]; Patrick et al. 2014 [Ref 9]).

3. **Cardiovascular pre-screening.** Patients with pre-existing cardiovascular disease, structural heart abnormalities, arrhythmias, or uncontrolled hypertension face elevated risk (Vitiello 2008 [Ref 33]).

4. **Do not crush or dissolve extended-release formulations.** This converts the PK profile from extended to immediate release, increasing toxicity risk and abuse potential.

5. **Drug holidays for children.** Periodic breaks mitigate growth suppression; should be planned with prescribing physician (Roche et al. 1979; Vitiello 2008 [Ref 33]).

6. **Emergency thresholds:** Ingestion >2 mg/kg or 60 mg IR without medical supervision warrants ED evaluation (Scharman et al. 2007 [Ref 39]).

7. **Benzodiazepines** are the appropriate first-line emergency management for stimulant toxicity (agitation, seizure) — not antipsychotics as first line.

### Contraindications (from prescribing literature and toxicology guidelines)

- **Absolute:** MAOIs (concurrent or within 14 days), history of hypersensitivity to MPH
- **Strong caution / relative:** Pre-existing cardiovascular disease, hypertension, hyperthyroidism, glaucoma (angle-closure), anxiety disorders, history of psychosis or mania, seizure disorder, substance use disorder

---

## Tolerance & Dependence

### Physical Dependence

Rated as **moderate** in the brief. No severe physical withdrawal syndrome analogous to opioids or benzodiazepines is documented in the therapeutic literature. Long-term OROS-MPH (52 weeks) study with a double-blind withdrawal phase found **no evidence of withdrawal or rebound** on discontinuation in adult ADHD patients at therapeutic doses (Buitelaar et al. 2012 [Ref 37]).

However, rebound effects can occur with abrupt cessation of short-acting formulations, including rare cases of acute dystonia (Efe et al. 2024 [Ref 34]).

### Psychological Dependence

Rated as **moderate** in the brief. The risk is strongly linked to **route and rate of administration**. Oral therapeutic dosing carries considerably lower psychological dependence liability than IV or intranasal use. The slower rate of DAT occupancy with oral MPH limits the intense "rush" associated with high abuse potential stimulants.

### Tolerance Formation

Acute pharmacodynamic tolerance to cardiovascular effects of MPH is well documented; the first-generation once-daily ER formulations (e.g., Ritalin SR) were associated with acute tolerance that blunted afternoon efficacy (Patrick et al. 2019 [Ref 6]). Modern formulations using ascending-dose release profiles (e.g., Concerta) were designed to counteract this.

Longer-term neuropharmacological tolerance (receptor downregulation, DAT upregulation) can develop with chronic use, particularly with non-therapeutic escalating doses.

### Dependence Formation Assessment

The brief states "moderately addictive with a high potential for abuse." The published literature supports:
- DEA Schedule II classification reflects established abuse potential (Preuss et al. 2026 [Ref — from PMID 30726003])
- Illicit use predominantly for cognitive enhancement (non-medical use) and recreational stimulant effects
- Abuse potential significantly lower than cocaine for same-dose DAT blockade due to the slow rate of rise in oral dosing (Volkow [Ref 2] and rate hypothesis literature)
- High potential for abuse in IV and intranasal routes (bypasses first-pass, rapid DAT occupancy)

---

## Interactions

### Tramadol — Flagged as "Lethal" in Brief

**⚠️ FLAG for editorial review:** The brief rates the tramadol–MPH interaction as "lethal." Published literature documents a **serious** interaction via two mechanisms:
1. **Additive seizure threshold lowering:** Both tramadol and MPH independently lower the seizure threshold. Co-administration magnifies this risk.
2. **Serotonergic potentiation:** Tramadol is a SNRI/opioid agonist with serotonergic effects; MPH increases synaptic norepinephrine; combined serotonergic/noradrenergic excess risks **serotonin syndrome**.

No published peer-reviewed case report of a human fatality specifically from MPH + tramadol co-administration was identified in this literature search. The "lethal" classification appears to be derived from indirect evidence (class-level effects). The severity rating requires primary source verification. This interaction is **serious/dangerous** and warrants strong caution wording, but the "lethal" label may not be supportable without case-level evidence. **Recommend editorial downgrade to "dangerous" with a note on seizure and serotonin syndrome risk pending further review.**

### MDMA — Flagged as "Dangerous" in Brief

The brief rates this interaction as "dangerous." Supporting evidence:
- MDMA primarily acts as a serotonin-releasing agent via SERT; MPH is primarily a DAT/NET reuptake inhibitor
- Both compounds increase sympathetic cardiovascular load (heart rate, blood pressure)
- Combined use could produce additive/synergistic cardiovascular strain
- Dolder et al. (2018 [Ref 24]) directly compared MPH and MDMA head-to-head in healthy subjects at equivalent cardiostimulant doses; combined use was not studied
- The "dangerous" rating appears plausible based on additive cardiovascular burden, but specific published clinical evidence for MPH + MDMA combination harm is limited
- **Flag:** Severity classification not confirmed against published pharmacological evidence specific to this combination

### Alcohol — Listed as "Unknown" in Brief

The brief lists this interaction as "unknown," which is **incorrect based on published evidence.** The alcohol–MPH interaction is well-documented:
- Ethanol inhibits CES1, increasing d-MPH plasma levels by ~40% Cmax, ~25% AUC (Patrick et al. 2007 [Ref 8])
- Forms ethylphenidate as a transesterification metabolite (Patrick et al. 2014 [Ref 9]; Koehm et al. 2010 [Ref 38])
- Potentiates subjective euphoria and abuse liability (Zhu et al. 2017 [Ref 10])
- **⚠️ FLAG:** The alcohol interaction severity classification in the database should be updated from "unknown" to "dangerous" or at minimum "caution" — the pharmacokinetic interaction is well-established and clinically meaningful.

### MAOIs — Not Listed in Brief (Major Omission)

**⚠️ FLAG:** The brief does not list MAOI interactions. This is a critical safety gap. MAOIs are an absolute contraindication with MPH:
- Risk of severe **hypertensive crisis** from excessive catecholamine accumulation
- All MPH ingestion in MAOI-treated patients requires emergency evaluation (Scharman et al. 2007 [Ref 39])
- **This contraindication must be added to the database.**

---

## Legal Status

| Jurisdiction | Status | Notes |
|---|---|---|
| **United States** | DEA **Schedule II** | High abuse potential; accepted medical use; No refills permitted |
| **United Kingdom** | **Class B** (Misuse of Drugs Act) / **Schedule 2** (Misuse of Drugs Regulations) | Prescription only; possession without Rx = criminal offense |
| **International (UN)** | **Schedule II** under 1971 Convention on Psychotropic Substances | Global treaty framework |
| **Canada** | **Schedule III** under Controlled Drugs and Substances Act (CDSA) | Requires valid prescription; trafficking/export = up to 10 yr imprisonment |
| **Australia** | **Schedule 8** (Controlled Drug) under TGA Poisons Standard | Specialist prescription required (paediatrician/psychiatrist in most states) |
| **EU** | Varies by member state | Generally controlled; prescription required; not uniformly scheduled across EU |

Sources: Dodd et al. 2025 [Ref 21], web-retrieved government sources [Refs 23, 41, 42].

---

## Clinical Trials

**Selected completed and notable trials:**

| NCT ID | Phase | Title / Focus | Status | Sponsor |
|---|---|---|---|---|
| NCT00254878 | Phase 3 | Comparison of MPH brands (Concerta vs Ritalin) in ADHD children 6–14 | Completed | Novartis |
| NCT04366609 | — | CES1 genotype and MPH response (INDICES WP6) | Completed | Mental Health Centre Copenhagen |
| NCT01673594 | Phase 4 | Prevention of stimulant-induced euphoria with opioid receptor antagonist | Completed | Massachusetts General Hospital |
| NCT00663442 | Phase 4 | Basic and clinical research on ADHD — MPH response | Completed | University of Illinois at Chicago |

**Landmark published trials:**
- **MTA Cooperative Group (1999) [Ref 31]:** 14-month RCT; medication management (MPH-based) superior to behavioral therapy and community care for ADHD core symptoms.
- **Cortese et al. (2018) [Ref 28]:** Lancet Psychiatry network meta-analysis of ADHD medications — most comprehensive NMA to date; MPH found effective across age groups.
- **Storebo et al. (2025) [Ref 11]:** Updated Cochrane review on MPH in children and adolescents with ADHD.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief. No community feedback analysis is required.

---

## Gaps & Flags

### ⚠️ Safety-Critical Flags (Require Human Review)

1. **Tramadol interaction classified as "lethal" in database** — No peer-reviewed case report of human fatality from MPH + tramadol specifically found. Interaction is serious (additive seizure threshold lowering + serotonin syndrome risk) but "lethal" label is not confirmed by substance-specific published evidence. **Recommend downgrade to "dangerous" with mechanism note.** Interaction warrants strong clinical caution regardless.

2. **Alcohol interaction classified as "unknown" in database** — This is incorrect. The MPH–ethanol interaction is well-documented in multiple RCTs and PK studies: ~40% Cmax increase, ethylphenidate formation, potentiated euphoria and abuse liability. **Recommend immediate upgrade to "dangerous/significant."**

3. **MAOI interaction completely absent from the database** — This is a critical safety omission. MAOIs are an absolute contraindication with MPH (risk of hypertensive crisis). Must be added.

4. **LD50 values (367 mg/kg oral rat; 50 mg/kg IV rat)** sourced from Novartis Ritalin Safety Data Sheet (web-retrieved), not peer-reviewed toxicology literature. Should be verified against published animal toxicology studies.

5. **DAT vs. NET binding affinity Ki values** — The web-retrieved values (DAT Ki ~193 nM, NET Ki ~38 nM for d-MPH) and the Hannestad 2010 PET finding that in vitro NET affinity exceeds DAT are not confirmed against a primary peer-reviewed source using human cloned transporters. Editorial discretion needed.

### Data Gaps

6. **SMILES string** — Not returned by the PubChem API call used. Can be obtained from PubChem CID 4158 directly.

7. **Melting point and aqueous solubility** — No published peer-reviewed source found for MPH HCl physical properties during this search.

8. **Intranasal (insufflated) PK data** — Formal controlled human PK studies of insufflated MPH are not well represented in published literature. The brief lists insufflated as the "primary ROA" — this appears to reflect a non-medical use context rather than the primary clinical route (oral). **FLAG:** Primary ROA in the database should be "oral"; insufflated should be listed as a secondary ROA associated with misuse/recreational use.

9. **MDMA interaction severity** — "Dangerous" classification has pharmacological plausibility (additive cardiovascular strain) but is not confirmed against published clinical evidence specific to the MPH + MDMA combination.

10. **Tolerance data fields are blank** — Published literature supports: acute pharmacodynamic tolerance to cardiovascular effects (well-documented); long-term neuroadaptive tolerance with chronic use. However, no quantified tolerance timeline from controlled studies was identified.

11. **Characterization = "emerging"** — This is clearly incorrect for a substance in continuous clinical use since 1955. Should be reclassified.

12. **EU legal status** — Varies significantly by member state; no uniform EU-level scheduling could be confirmed.